Ongoing symptoms following COVID infection and hospitalisation Infections and Infestations
Conditions
Interventions
Patients will be randomised on a 1:1:1 ratio. Those that are able to access only one of the two interventions (face to face or digital) will be randomised on a 2:1 ratio to the accessible intervention
Sponsors
University of Leicester
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Ongoing symptoms following COVID-19 infection that are deemed modifiable by a rehabilitation programme 2. Hospitalisation during an acute infection of COVID-19
Exclusion criteria
Exclusion criteria: 1. Unwilling to consent for the trial 2. Full recovery of symptoms reported by the patient (physical and psychological) 3. Persistent symptoms indicative of other significant medical conditions that require further investigation/management 4. Currently on or recently completed a course of COVID rehabilitation (previous 6 months) 5. Contraindications for exercise (American College of Sports Medicine)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Performance is measured using the Incremental Shuttle Walking Test at baseline and 8-week follow up | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. HRQOL is measured using the Functional Assessment of Chronic Illness Test- Fatigue total score at baseline and 8-week follow up 2. HRQOL is measured using the Nottingham extended Activities of Daily Living questionnaire at baseline and 8-week follow up 3. HRQOL is measured using the EuroQuol 5 domain at baseline and 8-week follow up 4. Breathlessness is measured using the Dyspnoea-12 at baseline and 8-week follow up 5. Cognitive impairment is measured using the Montreal Cognitive Assessment at baseline and 8-week follow up 6. Pain is measured using the Brief Pain Inventory at baseline and 8-week follow up 7. Symptoms of depression are measured using the Patient Health Questionnaire-9 at baseline and 8-week follow up 8. Symptoms of anxiety are measured using the General Anxiety Disorder 7 Questionnaire at baseline and 8-week follow up 9. Presence of sarcopenia is measured using the SARC-F at baseline and 8-week follow up 10. Quadriceps strength is measured using the Quadriceps Maximal Voluntary Contraction at baseline and 8-week follow up 11. Handgrip strength is measured using a grip strength dynamometer at baseline and 8-week follow up 12. Physical activity is monitored using the GENEActiv wrist-worn actigraphy device for 1 week following the initial study visit and between weeks 7-8 13. Breathing dysfunction is measured using the Nijmegan questionnaire at baseline and 8-week follow up 14. Functional capacity is measured using the Short Physical Performance Battery at baseline and 8-week follow up | — |
Countries
England, United Kingdom
Contacts
Public ContactGeorge Mills
Outcome results
None listed